Inhibition of platelet aggregability by losartan in essential hypertension

American Journal of Cardiology

Volumn 86, Issue 11, 2000, Pages 1188-1192

  Levy, Pavel J ^a   Yunis, Carla ^a   Owen, John ^b   Brosnihan, K Bridget ^a   Smith, Ronald ^a   Ferrario, Carlos M ^a,b  

^a Hypertension and Vascular Research Center   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN; PEPTIDE SFLRRN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PMIS 387; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; OLIGOPEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PROSPECTIVE STUDIES; RECEPTORS, THROMBIN; RECEPTORS, THROMBOXANE; VON WILLEBRAND FACTOR;

EID: 0034564087     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01200-5     Document Type: Article

References (26)

1. Abnormalities of rheology and coagulation in hypertension
2. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
3. Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects
4. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions
5. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia
6. Does hypertension confer a prothrombotic state? Virchow's triad revisited
7. The renin-angiotensin and fibrinolytic systems: Co-conspirators in the pathogenesis of ischemic cardiovascular disease
8. 2-induced contractions in canine coronary arteries
9. 2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats
10. 2-induced vasoconstriction in canine coronary arteries and human platelet aggregation
11. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys
12. Acute effects of angiotensin II on fibrinolysis in healthy volunteers
13. 2 (TP) receptors
14. Study of platelet adhesion in patients with uncomplicated hypertension
15. ACE inhibitor effects on platelet function in stages I-II hypertension
16. The human platelet thrombin receptor. Turning it on and turning it off
17. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
18. Von Willebrand factor and soluble E-selectin in hypertension: Influence of treatment and value in predicting the progression of atherosclerosis
19. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
20. Pathologic consequences of increased angiotensin II activity
21. Angiotensin II receptors on human platelets
22. Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists
23. Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation
24. The effects of once-daily amlodipine on platelet aggregation and blood pressure in patients with essential hypertension
25. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients
26. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor